Product & support information
DEA 7-OH Scheduling 2026: Status, Thresholds & Dates
As of September 19, 2026, federal law has two different tracks: MGPI, MGM-15, and MGM-16 are temporarily Schedule I; DEA's separate threshold proposal for 7-OH has not yet become an effective order.
Status table
| Substance or action | Current federal status | Key date |
|---|---|---|
| Mitragynine pseudoindoxyl (MGPI) | Temporarily Schedule I | Effective August 26, 2026 |
| MGM-15 | Temporarily Schedule I | Effective August 26, 2026 |
| MGM-16 | Temporarily Schedule I | Effective August 26, 2026 |
| 7-OH above DEA's proposed threshold | Notice of intent; no temporary order located as of this update | HHS comments closed September 10, 2026 |
| Mitragynine (MIT) | Not one of the three substances in the August 26 order | Check other federal and state requirements separately |
What the August 26 order did
DEA placed MGPI, MGM-15, and MGM-16 in Schedule I through August 26, 2028, unless the order is extended or replaced sooner. DOJ described limited enforcement discretion for incidental trace MGPI in an otherwise botanical kratom product. That policy leaves MGPI's legal status unchanged and excludes MGM-15, MGM-16, and deliberately added or concentrated MGPI.
What the 7-OH notice proposes
The notice proposes a threshold of more than 0.050% 7-OH on a dry-weight basis for botanical material. For specified synthetic or further-processed articles, it proposes more than 0.050% or more than 1mg of 7-OH in the article. HHS extended public comments through September 10, 2026. A notice of intent describes a planned action; the legal change occurs only when DEA publishes the temporary order.
Read the compound before the claim
- Identify the actual active compound, not only the brand name.
- Record whether the item is leaf, extract, tablet, gummy, liquid, or another processed form.
- Match the product to a lot or sample report and read the units and detection limits.
- Check the newest Federal Register document and the destination's current state law.
- Do not treat an FDA disclaimer, a “botanical” label, or a seller's shipping option as proof of legality.